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We previously developed virus like particles of rotavirus (RV) with VP2, VP6, and VP7 proteins (VLP2/6/7)
using stable High-ﬁve cell line. To evaluate the immunogenicity of our construct, we assessed the hu-
moral and cytokine responses induced by VLP2/6/7 in BALB/c mice immunized intra-peritoneally and
intra-rectally. Enzyme-linked immunosorbent assay (ELISA) and Relative quantitative (RQ) Real-time PCR
were used to evaluate the antibody (IgG and IgA) levels in serum and mRNA levels of IL-6, IL-10 and IFN-g
in spleen cells, respectively. Our results showed that VLP2/6/7 is capable of intra-peritoneal (I.P.) and
intra-rectal (I.R.) induction of serum IgG and IgA responses. IgA was detected in fecal samples of im-
munization groups by I.P. and I.R. routes. Interestingly, I.R. route induced higher IgA titer compared with
I.P. route which was statistically signiﬁcant. Moreover, mRNA levels of IL-6 and IFN-g were signiﬁcantly
elevated in mice immunized intra-peritoneally with VLP2/6/7 compared to control group. As such, the
mean change was 7.4 (P < 0.05) and 14.8 (P < 0.001) for IFN-g and IL-6, respectively. Likewise, the same
pattern was found when mice were immunized intra-rectally. Although elevated, the difference in the
mean change for IL-10 was not statistically signiﬁcant when compared to control group. Our ﬁndings
indicated that VLPs constructed via a stable insect cell line are able to induce both humoral and cellular
responses, a similar pattern as observed after immunization with live RVs.
 2014 Elsevier Ltd. All rights reserved.1. Introduction can lead to the development of disease in vaccinated children [14eRotaviruses (RVs), as a genus of the Reoviridae family, are a
common cause of severe diarrhea in children <5 years of age
worldwide, in addition to noroviruses [1e5]. Efforts to develop a RV
vaccine have begun in the late 1970s, and Rotashield was the ﬁrst
RV vaccine licensed but was withdrawn in 1999 by its manufacturer
because of its association with intussusception during post-
licensure surveillance [6e8]. Recently, RotaTeq and Rotarix, as
live attenuated vaccines, were developed and shown to efﬁciently
protect against severe diarrhea [9e13]. However, high degree of
genetic exchange and reversion of a live vaccine strain to a more
virulent state are main concerns that need to be addressed as theyteur Institute of Iran, Tehran,18]. Moreover, concerns regarding safety and efﬁcacy skewed re-
searchers’ focus on alternative vaccine candidates such as non-
living RV vaccines among which virus like particle (VLP)-based
vaccines have shown the most promising results [15].
Different expression systems such as baculovirus expression
vector system in insect cells have been used to produce RV VLPs
[19e28]. Administration of RV VLPs by different routes, intra-rectal
(I.R.), intra-nasal (I.N.), oral and parenteral has been investigated to
evaluate immune responses and it has been shown that VLPs are
able to induce antibody responses and protect animal models from
RV [29e35]. Moreover, looking at the immunogenicity of RV VLPs or
recombinant vaccines, the enhancement of immune response has
been found following the administration of different adjuvants
[30,34,36e38] although the induction of immunogenicity has been
also reported in the absence of adjuvants [30,35,39e41]. Compared
to subunit vaccines, a lower dose of VLPs needs to elicit a similar
protective response, as they mimic the structure of virus particles
[42]. Recently, we have developed VLP2/6/7 using a stable
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this study, we investigated the immunogenicity of our construct
following intra-peritoneal (I.P.) and I.R. administration in mice, and
our results indicated that VLPs are able to induce humeral re-
sponses (serum IgG and IgA, fecal IgA) consistent with others
[29,34]. Interestingly, efﬁcient IgA response was observed in feces
when administrated intra-rectally, indicating the importance of
local response because the intestinal tract is the portal for
ingestion RV.
Until now, there are few reports about the cytokine proﬁle
induced by RV VLPs. Previous studies have shown that VLPs
administered to mice can induce a mixed Th1/Th2 proﬁle of cyto-
kines very similar to which induced by live RV administered to
suckling mice [32,43]. In addition to humoral responses, we further
investigated cytokine proﬁle in immunized mice with VLPs using
I.P. and I.R. routes. Increased mRNAs level of cytokines was also
found, suggesting the induction of cellular immune response. Our
result suggests that I.P. and I.R. immunization with VLPs con-
structed via a stable insect cell line can elicit both humoral and
cellular immune responses, further highlights the role of VLPs as a
promising vaccine candidates.
2. Materials and methods
2.1. VLPs preparation
In our previous study, we have developed VLPs containing VP2,
VP6 and VP7 proteins of RV using a stable High-Five cell system
(Shoja et al., submitted for publication). High-Five insect cell line
stably and constitutively expressing VLP2/6/7 was grown in serum-
free SF900 medium (Life Technologies, Carlsbad, CA) in the pres-
ence of G418 and hygromycin antibiotics up to two weeks at 28 C.
Cell supernatants were clariﬁed by centrifugation at 2000  g for
15 min at 4 C. VLPs were then puriﬁed by ultracentrifugation
sedimentation through 25% sucrose cushion at 100,000  g for
75 min. Puriﬁed VLPs were ﬁnally resuspended in 1  PBS as pre-
viously described [44,45].
2.2. Immunization experiments
To evaluate the induction of immune responses by VLP2/6/7,
female BALB/c mice 6e8 weeks of age were used to inject intra-
peritoneally and intra-rectally with VLPs. Ten mice (6 mice for I.P.
and 4 mice for I.R.) were used for each immunization and control
groups and checked regularly for signs of toxicity, and remained
healthy up to the end of the immunization protocol. BALB/c mice
were injected intra-peritoneally and intra-rectally with 20 mg of
puriﬁed VLPs resuspended in 100 ml of PBS. For I.R. immunization,
mice were ﬁrst instigated to defecate, and then immunization was
gradually performed. Mice were monitored for 5 min to make sure
there is no liquid evacuating through the anus during this time. The
immunization schedule was based on a 3-dose regimen, where the
booster inoculations were administered at 2 and 4 weeks after the
primary injection. Blood samples were drawn from the retro-
orbital vein 2 days before the priming dose (pre-immunization)
and 7 days after each administration. Fecal samples were collected
from each mouse on day 42 (7 days after the last immunization).
The mice were then sacriﬁced and spleens were removed for
cytokine proﬁle investigation. All experiments were performed
according to the Helsinki guidelines.
2.3. Enzyme-linked immunosorbent assay (ELISA)
The presence and the titer of speciﬁc anti-VLP antibodies were
evaluated in sera collected from immunized mice by ELISA. Nunc-Immuno F8 MaxiSorp plates (Thermo Scientiﬁc) were coated
with 1:80 dilution of puriﬁed VLPs resuspended in PBS. Plates were
then incubated with dilutions of heat-inactivated mouse sera and
mouse feces ranging from 1:250 to 1:64,000 and 1:40 to 1:10,240,
respectively. After 4 times washes with PBS-Tween (0.1%) wells
were incubated 2 h at 37 C with Goat anti-mouse IgG-HRP and
Goat anti-mouse IgA (Abcam) antibodies (1:4000 dilution). Positive
reactions were visualized with TMB solution and stopped with 2 N
sulfuric acid. Absorbance was determined at 450 nm and reactions
were considered positive when exceeding the mean
absorbance þ 2 standard deviations (SD) of equal dilutions of pre-
immune sera or feces taken from control group.
2.4. RNA extraction from spleen
Total RNAwas extracted from the spleen cells of immunized and
control mice using Trizol total RNA isolation reagent (Gibco BRL,
Life Technologies, USA) according to the manufacturer’s in-
structions. Extracted RNAwas eluted in 80 ml RNase-free water, and
to eliminate contaminating genomic DNA, the RNA samples were
treated with RNase-Free DNase I (Fermentase) according to the
manufacturer’s instructions. RNA purity and concentration were
determined using the NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientiﬁc). Based on the absorbance ratio at 260/
280 nm (range from 1.8 to 2, Mean  standard error of the mean
(SEM) ¼ 1.878  0.03492) and at A260/A230 nm (range from 2 to 2.2,
Mean  SEM ¼ 2.271  0.03551), all RNA samples were pure and
protein free. Total RNA from 20 samples (immunized and control
mice) was then adjusted to a ﬁnal concentration of 1.5 mg/ml before
stored at 80 C.
2.5. cDNA synthesis
cDNA was synthesized from total RNA (1.5 mg) using RT enzyme
mix and 2 RT reaction mix (includes oligo (dT)20 and random
hexamers) for one cycle in aﬁnal volumeof 20 ml as follows: 25 C for
10 min, 50 C for 30 min and 85 C for 5 min using SuperScript III
First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad,
California, CA) according to the manufacturer’s instructions. The
cDNAwas then diluted in nuclease free water and stored at 20 C.
2.6. Relative quantitative (RQ) real-time PCR
Target genes (IL-6, IL-10 and IFN-g) were relatively quantiﬁed by
real-time PCR with SYBR GreenER qPCRSuperMix Universal
(Invitrogen, Carlsbad, California, CA) on the Corbett Research Rotor-
Gene (Qiagen, USA). Brieﬂy, PCR ampliﬁcation reactions were
performed in 20 ml reaction mixtures containing cDNA (10 fold
diluted), 2 Sybr Green supermix and 10 pmol of each primer pair
(Table 1). The reactions were incubated at 95 C for 10 min,
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60 s. Distilled water (DW) was used as a negative control. A melting
curve analysis was performed to conﬁrm single gene-speciﬁc peaks
by heating samples from 60 to 99 C at the end of the ampliﬁcation
cycles.
The linearity and accuracy of Real-time RT-PCR were evaluated
using b-actin (Reference gene) standard curve derived from
amplifying serially diluted pooled cDNA (a 10-fold dilution series).
These diluted pooled cDNAwere also used for intra- and inter-assay
experiments. A serially diluted cDNAwas ampliﬁed as triplicates on
the same plate to assess the intra-assay accuracy with the standard
deviation of the mean CT value ranged from 0.07 to 0.87, with co-
efﬁcients of variation < 5%. In addition, three independent assays
were used to assess the inter-assay accuracy. The standard devia-
tion of the mean CT value ranged from 0.17 to 1.6, with coefﬁcients
of variation < 5%. The linearity and accuracy were determined byFig. 1. Anti-VLP2/6/7 IgG and IgA speciﬁc responses in serum samples of BALB/c mice immu
mice at indicated serum dilutions a week after each intra-peritoneally administration of VLPs
dilutions a week after each intra-rectally administration of VLPs (*: P value < 0.05). Bars rethe correlation coefﬁcient (R2 ¼ 1) and by the equation for the
standard curve (y ¼ 3.415X þ 34.90).
IL-6, IL-10 and IFN-g expression was analyzed according to the
2DDCT method and the levels of each cytokine normalized to the
b-actin cDNA amount [46]. The relative values of each cytokine
were expressed as the fold-increase of the immunized group over
the control group to compare mRNA levels between immunized
and control groups.
2.7. Statistical analysis
Statistical analysis was performed with GraphPad Prism soft-
ware, Version 5. Two-way ANOVA was used to analyze humoral
immune responses. Quantiﬁcation of cytokines mRNA level was
assessed using the non-parametric test, one-way ANOVA. P
value < 0.05 was considered statistically signiﬁcant.nized intra-peritoneally and intra-rectally. (A and C) O.D.450 values observed per each
(*: P value < 0.05). (B and D) O.D.450 values observed per each mice at indicated serum
present the mean  standard error of the mean (SEM).
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3.1. In vivo humoral immune response induced by VLP2/6/7 in sera
ELISA tests were performed on Nunc-Immuno F8 MaxiSorp
plates coated with puriﬁed VLPs. As indicated in Fig. 1A, I.P. im-
munization protocols with VLPs induced anti-VLP IgG titers,
reaching from highest dilutions of 1:4000 (P < 0.01) to 1:16,000
(P < 0.05) for single and double boost immunization, respectively.
For anti-VLP IgA titers, the highest dilution for both single and
double boost immunizationwas found 1:16,000 (P< 0.01) (Fig. 1C).
Moreover, immunizing mice with I.R. induced anti-VLP IgG titers,
reaching a highest dilution of 1:4000 (P < 0.0001) after double
boost immunization (Fig. 1B), whereas the highest dilutions for
anti-VLP IgA titers after single and double boost immunization
were found 1:1000 (P < 0.05) and 1:16,000 (P < 0.01), respectively
(Fig. 1D). Moreover, as indicated in Fig. 2, IgA was detected in fecal
samples collected from mice immunized intra-rectally and intra-
peritoneally, reaching from highest dilutions of 1:640 (P < 0.05)
to 1:160 (P < 0.05), respectively. However, low IgA titer was found
in feces when the mice were immunized intra-peritoneally
compared to intra-rectally.
Our results showed that the I.P. and I.R. administration of VLPs
generated by the stable double transfected High-Five cells is able to
induce high levels of serum IgG and IgA titer although the differ-
ence between two routes (I.P. vs. I.R.) was not statistically signiﬁ-
cant (P > 0.05). In addition, detectable IgA titers in fecal samples
suggested that I.R. route can induce efﬁcient IgA response in in-
testinal tract compared to I.P. route.3.2. IL-6, IL-10 and IFN-g relative mRNA level in mice spleen
Prior to assess the relative expression levels of target genes, the
linearity and accuracy of the real-time PCR were conﬁrmed (Fig. 3).
The mRNA levels of IL-6, IL-10 and IFN-g genes were normalized
and analyzed by the comparative CT method. Analysis of our results
indicated an increase in mRNA levels of cytokine proﬁle. Looking at
the mRNA level for IFN-g and IL-6, signiﬁcant mean changes inFig. 2. Anti-VLP2/6/7 IgA speciﬁc responses in fecal samples of BALB/c mice immu-
nized intra-peritoneally and intra-rectally. O.D.450 values observed per each mice at
indicated fecal dilutions a week after last intra-peritoneally and intra-rectally admin-
istration of VLPs (*: P value < 0.05). Bars represent the mean  SEM.intra-peritoneally immunized mice compared to control group
were detected. The mean change observed for IFN-g and IL-6 was
7.4 (P < 0.05) and 14.8 (P < 0.001), respectively. Likewise, in VLP-
immunized mice the level of IL-10 mRNA increased by a mean of
1.98 fold, however, the difference was not statistically signiﬁcant
(P > 0.05) when compared to control group. Additionally, similar
pattern was found when mice were immunized intra-rectally with
VLPs. In this group, the mean change for IFN-g and IL-6 was found
to be 8.8 (P < 0.05) and 14.5 (P < 0.001), respectively. For IL-10 the
mean change was 4.9 (P > 0.05) (Fig. 4). However, comparing
immunized mice groups based on the immunization routs (I.P. vs.
I.R.) there was no signiﬁcant difference in the relative mRNA levels
of IL-6 and IFN-g (P > 0.05).
4. Discussion
Diarrhea, as the most common illnesses in children, results from
various pathogenic agents particularly enteric viruses. RVs, as a
major cause of severe acute gastroenteritis, are responsible for
around 6% of diarrheal episodes and 20% of diarrheal related deaths
in children <5 years of age in developing countries [47,48]. Data
obtained from epidemiological and hospital-based studies supports
the necessity of further investigation to prevent RV infection and
vaccine development [49,50]. Enormous efforts have been made to
develop a safe and effective vaccine. So far, non-living vaccines
particularly VLPs-based vaccines have provided themost promising
results. In line with this, a wide range of homologous or heterolo-
gous VLPs have been developed.
We have previously constructed VLP2/6/7 using stable High-Five
cell system (Shoja et al., submitted for publication). In this study we
evaluated the immunogenicity of VLP2/6/7 in BALB/c mice
administered by I.P. and I.R. routes, and investigated the mRNA
levels of IL-6, IL-10 and IFN-g using relative quantitative real-time
PCR.
Our results showed that speciﬁc serum anti-VLP IgG was
induced following VLP administration regardless of I.P. and I.R.
routes although I.P. immunization group induced a 1-dilution rise
in the speciﬁc serum anti-VLP titers compared to I.R. immunized
group. A progressive increase of speciﬁc serum anti-VLP IgA
effectively elicited in both the I.P. and I.R. immunization groups.
Our ﬁndings showed that I.P. route is able to induce a signiﬁcant
IgG and IgA responses, whereas, I.R. route induced a stronger IgA
than IgG response. Moreover, IgA was detected in fecal samples of
immunization groups by I.P. and I.R. routes. Interestingly, I.R. route
was found to induce signiﬁcantly higher IgA titer compared to I.P.
route. In previous studies, parenterally administered live RV or
VLPs have been shown high levels of serum and fecal antibody in
animal models [30,33,35,51e53]. In 1996 and 2003, Conner et al.,
and Bertolotti-Ciarlet et al., documented the immunogenicity and
protective efﬁcacy of VLPs administered intra-muscularly to rab-
bits and mice, respectively [30,52]. Parenteral administration of RV
vaccine has been demonstrated to be protective in several animal
models. Moreover, mucosally (oral and I.N. routes) administered
VLPs have been indicated to elicit serum and intestinal antibodies
[30,35,54,55] although I.N. route offered high level of antibodies
and protection against virus challenge [30,54]. In 2006, Parez
et al., ﬁrst documented the induction of high levels of mucosal and
systemic antibodies via rectal administration of VLPs [34]. Similar
ﬁndings were also found following mice immunization via I.N. and
I.R. routes although I.R. route displayed more efﬁcient response in
intestinal tract [29]. Our ﬁndings were in agreement with previous
studies suggesting VLPs can induce IgG and IgA responses through
both the I.P. and I.R. routes, providing further evidence that VLPs
are immunogenic. We also demonstrate that I.R. route induces
higher IgA response than I.P. route in the intestinal tract, similar to
Fig. 3. Real-time RT-PCR was performed with primer pair of b-actin as housekeeping gene. (A) Intra-assay accuracy and Inter-assay reproducibility of the b-actin cDNA amounts by
Real-time RT-PCR. (B) Linearity and accuracy of b-actin Real-time RT-PCR. 10-fold serial dilutions of the total RNA standard starting from 10 to 1000 ng were ampliﬁed in triplicate by
Real-time RT-PCR. The linearity and accuracy were determined by the correlation coefﬁcient (R2 ¼ 1) and by the equation for the standard curve (y ¼ 3.415X þ 34.90).
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most efﬁcient [54,56,57].
In addition to antibody responses, cellular immune responses
have also been investigated in few studies. Considering the
immunogenicity of our VLP construct, we further evaluated the
mRNA levels of IFN-g a representative of Th1 cytokines, IL-10 a
representative of Th2 cytokines, and IL-6 a representative of pro-
inﬂammatory cytokines. Signiﬁcantly higher IL-6 and IFN-g
mRNA levels were found in immunized groups by both I.P. and I.R.
routes. Although not signiﬁcant, an increased fold of IL-10 mRNA
level was observed in immunized group compared to control
groups. In 2001, Fromantin et al., have shown for ﬁrst time thatFig. 4. mRNA levels of IL-6, IL-10 and IFN-g quantiﬁed by relative quantitative (RQ)
Real-time RT-PCR of spleen cells RNA extracts of BALB/c mice immunized with VLP2/6/
7 intra-peritoneally and intra-rectally. Bars represent the mean  SEM.I.N. immunization of mice with VLPs induces high IFN-g and IL-10
production in spleen and cervical lymph nodes (CLN) [32]. In
addition, in the study of Agnello et al. [29], they also reported that
I.N. and I.R. immunizations with VLPs induced IFN-g production
in spleen and Peyer’s patch cells. Similar results have also been
reported for the cellular immune responses following I.N. im-
munization of mice with VLPs where IL-10, IL-17, IL-2 and IL-4
were induced in spleen and CLN, whereas I.R. immunization
only induced IL-2 and IL-17, but not IL-10 and IL-4, in spleen,
lumbar lymphoid nodes (LLN) and mesenteric lymphoid nodes
(MLN) [43]. A similar cellular immune response was also
observed by homologous and heterologous strains of live RV
administered orally to suckling mice [58]. Our results showed that
VLPs increased IFN-g and IL-10 mRNAs level in mice immunized
intra-peritoneally and intra-rectally which are agreement with
the previous reports although the increased IL-10 level was not
statistically signiﬁcant. We also reported increased IL-6 mRNA
level in mice immunized intra-peritoneally and intra-rectally
which was not reported in previous studies using mice models,
suggesting that VLPs may induce high inﬂammatory stimulus in
immunization group. Moreover, cytokine patterns of our study
were similar to previous reports described in human study
[43,59e61].
In summary, our ﬁndings indicated that VLPs constructed via a
stable insect cell line not only induce humoral immune responses
but also elicit cellular immune responses in mice administered
intra-peritoneally and intra-rectally. Interestingly, the immune
response resulted from VLPs suggests a similar pattern observed
from studies carried out by live RVs, further highlighting the
importance of VLPs for vaccine development.Acknowledgments
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